Do you want to read an article? Please log in or register.
Switching from omalizumab to mepolizumab: real-life experience from Southern Italy
Asthma
RECOMMENDED
Related content
Asthma
Real-life Efficacy of Omalizumab After 9 Years of Follow-up
Allergy Asthma Immunol Res.
Menzella F, Galeone C, Formisano D, Castagnetti C, Ruggiero P, Simonazzi A, Zucchi L
doi: 10.4168/aair.2017.9.4.368.
RECOMMENDED
Asthma
Frequency of Tiotropium Bromide Use and Clinical Features of Patients with Severe Asthma in a Real-Life Setting: Data from the Severe Asthma Network in Italy (SANI) Registry
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
J Asthma Allergy
Puggioni F, Brussino L, Canonica GW, Blasi F, Paggiaro P, Caminati M, Latorre M, Heffler E, Senna G, Severe Asthma Network in Italy (SANI) group.
doi: 10.2147/JAA.S274245
RECOMMENDED
Asthma
Treatment Eligibility of Real-life Mepolizumab-treated Severe Asthma Patients
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
J Allergy Clin Immunol Pract.
Richards LB, van Bragt JJMH, Aarab R, Longo C, Neerincx AH, Sont JK, Weersink EJM, Braunstahl GJ, Brinke AT, Bel EHD, Maitland-van der Zee AH
doi: 10.1016/j.jaip.2020.04.029.
COMMENTED
Duration of the efficacy of omalizumab after treatment discontinuation in 'real life' severe asthma
Thorax.
Vennera MDC, Sabadell C, Picado C; Spanish Omalizumab Registry
doi: 10.1136/thoraxjnl-2017-
Asthma
Omalizumab in children with uncontrolled allergic asthma: Review of clinical trial and real-world experience
J Allergy Clin Immunol.
Chipps BE, Lanier B, Milgrom H, Deschildre A, Hedlin G, Szefler SJ, Kattan M7, Kianifard F, Ortiz B, Haselkorn T, Iqbal A, Rosén K, Trzaskoma B, Busse WW
doi: 10.1016/j.jaci.2017.03.002.
RECOMMENDED
Asthma
Clinical Determinants of Successful Omalizumab Therapy in Severe Allergic Asthma Patients: 4-Year-Long, Real-Life Observation
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
J Asthma Allergy
Kucharczyk A, Więsik-Szewczyk E, Poznańska A, Jahnz-Różyk K
doi: 10.2147/JAA.S282203
Asthma
Real-life effectiveness of omalizumab in severe allergic asthma above the recommended dosing range criteria
Clin Exp Allergy.
Hew M, Gillman A, Sutherland M, Wark P, Bowden J, Guo M, Reddel HK, Jenkins C, Marks GB, Thien F, Rimmer J, Katsoulotos GP, Cook M, Yang I, Katelaris C, Bowler S, Langton D, Wright C, Bint M, Yozghatlian V, Burgess S, Sivakumaran P, Yan KY, Kritikos V, Peters M, Baraket M, Aminazad A, Robinson P, Jaffe A, Powell H, Upham JW, McDonald VM, Gibson PG
doi: 10.1111/cea.12774.
RECOMMENDED
Asthma
Real-World Multicenter Experience with Mepolizumab and Benralizumab in the Treatment of Uncontrolled Severe Eosinophilic Asthma Over 12 Months
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 3
Recommended by
Dr Marcus Hesse, Faculty Member
J Asthma Allergy
Kayser MZ, Drick N, Milger K, Fuge J, Kneidinger N, Korn S, Buhl R, Behr J, Welte T, Suhling H
doi: 10.2147/JAA.S319572
Asthma
Omalizumab versus Mepolizumab as add-on therapy in asthma patients not well controlled on at least an inhaled corticosteroid: A network meta-analysis
J Asthma.
Nachef Z, Krishnan A, Mashtare T, Zhuang T, Mador MJ
doi: 10.1080/